Shah Gaurav 4

What Happened

• Gaurav Shah, CEO of Rocket Pharmaceuticals (RCKT), received two equity awards on February 11, 2026: 286,028 restricted stock units (RSUs) and a derivative award representing an option to acquire 870,648 shares. Both grants show an acquisition price of $0.00 (awarded as compensation, not an open-market purchase).

Key Details

• Transaction date: February 11, 2026; Form 4 filed February 13, 2026 (filed within the normal reporting window).
• Award amounts and prices:
  • 286,028 RSUs @ $0.00 (acquired) — RSUs convert to common stock on a 1:1 basis (Footnote F1).
  • 870,648-share option @ $0.00 (derivative award) — represents the right to purchase those shares (Footnote F3).
• Vesting schedule:
  • For the RSUs: one-third vests on February 11, 2027; remaining shares vest in equal quarterly installments over the following two years (Footnote F2).
  • For the option: one-third becomes exercisable on February 11, 2027; remaining vest quarterly over the next two years, subject to continued employment (Footnote F3).
• Shares owned after the transaction: not specified in the provided filing.
• Transaction code: A (award/grant). No sale, cashless exercise, 10b5-1 plan, or tax-withholding sale is indicated in the filing.

Context

• These awards are compensation grants (not market purchases) and are subject to multi-year vesting tied to continued employment. Such grants are common for executives and do not by themselves indicate immediate buying or selling activity in the open market.